Newly published research in Drug Discovery Today highlights the value of pharma companies collaborating to fix shared challenges.
The peer reviewed research from the Pistoia Alliance, a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups that work together to lower barriers to innovation in R&D, highlights the benefits of a project called Controlled Substance Compliance Services (CSCS) which helps companies manage the legal requirements around using managing the controlled substances used in pharmaceutical research.
CSCS was developed in response to companies needing to collaborate across borders on projects. When moving compounds there is a need to comply with regulations around the use of controlled substances in different regions and countries, and through CSCS, companies are easily able to manage the increasingly complicated regulations and ensure they remain fully compliant.
Anne Dunlop, from the Pistoia Alliance, and senior author of the research said: “With the rapidly evolving legislation around controlled substances it can be increasingly difficult for large organizations managing research across different countries and regions to ensure they are fully compliant with the myriad legislation. However, through CSCS, these companies now more easily manage this through a single integrated system.”
The Pistoia Alliance provided the interpretation of the legislation and encouraged the development of commercial products with shared risk funding from AstraZeneca, GlaxoSmithKline, Merck, Novartis and Roche. The commercial products are now available from Scitegrity and ChemAxon/PatCore. The CSCS project has now established an expert community to ensure the guidelines are maintained and where required, further expanded.
Michael Braxenthaler, President of the Pistoia Alliance, added: “CSCS is an excellent example of how through cooperation between different companies, it is possible to develop an excellent system which benefits the industry as a whole. While ensuring compliance with controlled substances will not produce the next blockbuster drug for a company, it can be used to save both time and money, ensuring scientists are free to concentrate on the research.”
The paper can be found at http://www.sciencedirect.com/science/article/pii/S1359644614003870